Pancreatic Cancer Clinical Trial
Official title:
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Verified date | October 2022 |
Source | Ipsen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic pancreatic adenocarcinoma. This study will assess the following regimen: • nal-IRI + 5-fluorouracil (5-FU)/leucovorin (LV) + oxaliplatin The study will be conducted in two parts: Part 1, consisting of an initial dose exploration (Part 1A) followed by dose expansion (Part 1B) of the irinotecan liposome injection +5-FU/LV + oxaliplatin regimen and Part 2, consisting of a comparison of irinotecan liposome injection-containing regimen versus nab-paclitaxel plus gemcitabine. The comparative Part 2 was removed in a protocol amendment, dated 11 April 2018 (Version 6.0), before it was initiated, as this comparative part of the study is being undertaken as a stand-alone phase III study D-US-60010-001. This CSR only pertains to the single-arm dose exploration and dose expansion Part 1 results and no further reference is made to the comparative Part 2.
Status | Completed |
Enrollment | 56 |
Est. completion date | February 15, 2021 |
Est. primary completion date | February 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed adenocarcinoma of the pancreas that has not been previously treated in the metastatic setting - Unresectable, locally advanced or metastatic disease; diagnosed within 6 weeks prior to screening - At least one tumor lesion measurable by CT or MRI scan (according to RECIST v1.1) - ECOG performance status of 0 or 1 at screening and within 72 hours prior to first dose if first dose occurs more than 72 hours post-screening - Adequate hematological, hepatic, renal and cardiac function - Recovered from the effects of any prior surgery or radiotherapy - Patient has a Karnofsky performance status (KPS) = 70 at Screening, and within 72 hours prior to date of first dose if first dose occurs more than 72 hours after screening (Part 1B only) Exclusion Criteria: - Prior treatment of pancreatic cancer in the metastatic setting (or locally advanced setting) with surgery (placement of stent is allowed), radiotherapy, chemotherapy or investigational therapy - Prior treatment of pancreatic cancer with chemotherapy in adjuvant setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related toxicities present - Uncontrolled Central Nervous System (CNS) metastases - Clinically significant gastrointestinal disorder - History of any second malignancy in the last 3 years. Patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible - Presence of any contraindications for nal-IRI, irinotecan, 5-FU, leucovorin, oxaliplatin - Use of strong CYP3A4 or inducers or presence of any other contra indications for irinotecan - Pregnant or breast feeding - Neuroendocrine or acinar pancreatic carcinoma - Serum albumin < 3 g/dL at screening visit and within 72 hours prior to first dose if first dose occurs more than 72 hours post screening - Patients with symptoms and signs of clinically unacceptable deterioration of primary disease at time of screening - Previous treatment with irinotecan-based, nab-paclitaxel-based or gemcitabine-based resulting in disease progression |
Country | Name | City | State |
---|---|---|---|
Australia | Flinders Medical Centre | Bedford Park | |
Australia | Box Hill Hospital | Lilydale | |
Australia | St. John of God Health Care - Subiaco | Subiaco | Western Australia |
Spain | Hospital Universitario Vall d'Hebron | Barcelona | |
Spain | Hospital General Universitario de Elche | Elche | Alicante |
Spain | Hospital Universitario de Fuenlabrada | Fuenlabrada | Madrid |
Spain | Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal (CIOCC) | Madrid | |
United States | University of Colorado (CU) Cancer Center - Anschutz Cancer Pavilion | Aurora | Colorado |
United States | Arizona Center for Cancer Care | Avondale | Arizona |
United States | Eastern Maine Medical Cancer Care | Brewer | Maine |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Lahey Hospital & Medical Center | Burlington | Massachusetts |
United States | Oncology/Hematology Care Clinical Trials, LLC | Cincinnati | Ohio |
United States | Texas Oncology Methodist Dallas Cancer Center | Dallas | Texas |
United States | Willamette Valley Cancer Institute & Research Center | Eugene | Oregon |
United States | Texas Oncology-Fort Worth 12 Ave | Fort Worth | Texas |
United States | Gettysburg Cancer Center | Gettysburg | Pennsylvania |
United States | Greenville Health System | Greenville | South Carolina |
United States | Houston Methodist Cancer Center and Institute of Academic Medicine | Houston | Texas |
United States | Oncology Consultants - Houston | Houston | Texas |
United States | Mayo Clinic Cancer Center | Jacksonville | Florida |
United States | US Oncology - Comprehensive Cancer Centers of Nevada (CCCN) | Las Vegas | Nevada |
United States | UCLA Hematology Oncology - Ventura | Los Angeles | California |
United States | Joe Arrington Cancer Research and Treatment Center - Lubbock | Lubbock | Texas |
United States | University of Miami | Miami | Florida |
United States | University of South Alabama | Mobile | Alabama |
United States | University of South Alabama - Mobile | Mobile | Alabama |
United States | University of Oklahoma Health Sciences Center (OUHSC) Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | Oncology Hematology West PC dba Nebraska | Omaha | Nebraska |
United States | University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center | Orange | California |
United States | Mayo Clinic Hospital | Phoenix | Arizona |
United States | Mayo Clinic Cancer Center - Rochester | Rochester | Minnesota |
United States | Texas Oncology, P.A. | San Antonio | Texas |
United States | Maryland Oncology Hematology | Silver Spring | Maryland |
United States | Medical Group of the Carolinas - Spartanburg Regional Health Services | Spartanburg | South Carolina |
United States | Holy Name Medical Center | Teaneck | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Ipsen |
United States, Australia, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT) | Adverse events (AEs) were considered to be DLTs if they occurred during the safety evaluation period (i.e, 28 days of Cycle 1; or 14 days after the second dose of study treatment if there was a treatment delay) and were deemed related to the study treatment regimen. Any AE that was related to disease progression was not considered a DLT. | From the start of the first study treatment (Cycle 1 Day 1) up to 14 days after the second dose of study treatment, maximum of 42 days | |
Secondary | Median Progression Free Survival (PFS) | The PFS was defined as the time from date of first study treatment to the first documented radiographical progression of disease (PD), per investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death from any cause, whichever comes first. The PFS was calculated using Kaplan-Meier technique. | RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter (maximum of 278 weeks). | |
Secondary | Best Overall Response (BOR) | The BOR was defined as the best response (complete response [CR] + partial response [PR] + stable disease [SD]) recorded from the start of study treatment until disease progression or start of new anticancer therapy using RECIST Version 1.1. | RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks). | |
Secondary | Overall Response Rate (ORR) | The ORR was defined as the percentage of participants with a BOR characterized as either a CR or PR relative to the total number of evaluable participants using RECIST Version 1.1. Evaluable participants were defined as treated participants with measurable disease at baseline. | RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks). | |
Secondary | Disease Control Rate (DCR) | The DCR was defined as percentage of participants with CR or PR or SD or Non-PD/Non-CR, per RECIST Version 1.1 relative to total number of treated participants with measurable disease at baseline. | At Week 16 | |
Secondary | Median Overall Survival (OS) | The OS was the time from date of first study treatment to the date of death from any cause. Participant survival data were collected from all available sources. The OS was calculated using Kaplan-Meier technique. | RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks). | |
Secondary | Median Duration of Response (DoR) | The DoR was defined as the time from the first date of response (CR or PR) to first date of documented radiographical PD, per investigator using RECIST Version 1.1. This only applied to participants with CR or PR. If a participant was given a new anticancer therapy prior to first response, DoR was not calculated. The DoR was calculated using Kaplan-Meier technique. | RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|